Evaluation of methylation biomarkers for detection of circulating tumor DNA and application to colorectal cancer

Genes

Volumn 7, Issue 12, 2016, Pages

  Mitchell, Susan M ^a   Ho, Thu ^a   Brown, Glenn S ^a   Baker, Rohan T ^b   Thomas, Melissa L ^b   McEvoy, Aidan ^b   Xu, Zheng Zhou ^a   Ross, Jason P ^a   Lockett, Trevor J ^a   Young, Graeme P ^c   Lapointe, Lawrence C ^b   Pedersen, Susanne K ^b   Molloy, Peter L ^a  

^a CSIRO   (Australia)

^b Clinical Genomics Pty Ltd   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

BCAT1; Biomarkers; Circulating tumor DNA; Colorectal cancer; Epigenetics; GRASP; Hypermethylation; IKZF1; IRF4 SDC2; Liquid biopsy; Plasma; SEPT9

Indexed keywords

BCAT1 PROTEIN; BETA SYNUCLEIN; BIOLOGICAL MARKER; EFEMP1 PROTEIN; FIBROBLAST GROWTH FACTOR 5; FOX12 PROTEIN; GRASP PROTEIN; HOXA2 PROTEIN; HOXA5 PROTEIN; IKZF1 PROTEIN; INTERFERON REGULATORY FACTOR 4; PROTEIN; SLC6A15 PROTEIN; SYNDECAN 2; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR SOX; TRANSCRIPTION FACTOR SOX 21; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 471; ZSCAN18 PROTEIN;

ADULT; ARTICLE; BCAT1 GENE; BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PATIENT; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; EFEMP1 GENE; EVALUATION STUDY; FEMALE; FGF5 GENE; FOXI2 GENE; GATA2 GENE; GENE AMPLIFICATION; GENE DELETION; GENE INSERTION; GENE MUTATION; GRASP GENE; HOXA2 GENE; HOXA5 GENE; HUMAN; IKZF1 GENE; IRF4 GENE; LEUKOCYTE; MALE; PDX1 GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; SDC2 GENE; SENSITIVITY ANALYSIS; SLC6A15 GENE; SNCB GENE; SOX21 GENE; ZNF471 GENE; ZSCAN18 GENE;

EID: 85006762281     PISSN: None     EISSN: 20734425     Source Type: Journal    
DOI: 10.3390/genes7120125     Document Type: Article

References (37)

1. Bordi, P.; Del Re, M.; Danesi, R.; Tiseo, M. Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. Transl. Lung Cancer Res. 2015, 4, 584–597.
2. El Messaoudi, S.; Mouliere, F.; Du Manoir, S.; Bascoul-Mollevi, C.; Gillet, B.; Nouaille, M.; Fiess, C.; Crapez, E.; Bibeau, F.; Theillet, C.; et al. Circulating DNA as a strongmultimarker prognostic tool for metastatic colorectal cancer patient management care. Clin. Cancer Res. 2016, 22, 3067–3077.
3. Li, Y.; Fu, X.-H.; Yuan, J.-Q.; Yang, Z.-Y.; Mao, C.; Dong, X.-M.; Tang, J.-L.; Wang, S.-Y. Colorectal cancer: Using blood samples and tumor tissue to detect K-ras mutations. Expert Rev. Anticancer Ther. 2015, 15, 715–725.
4. Marcinkowska-Swojak, M.; Handschuh, L.; Wojciechowski, P.; Goralski, M.; Tomaszewski, K.; Kazmierczak, M.; Lewandowski, K.; Komarnicki, M.; Blazewicz, J.; Figlerowicz, M.; et al. Simultaneous detection of mutations and copy number variation of NPM1 in the acute myeloid leukemia using multiplex ligation-dependent probe amplification. Mutat. Res.-Fundam. Mol. Mech. Mutagen. 2016, 786, 14–26.
5. Thierry, A.R.; Mouliere, F.; El Messaoudi, S.; Mollevi, C.; Lopez-Crapez, E.; Rolet, F.; Gillet, B.; Gongora, C.; Dechelotte, P.; Robert, B.; et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. Nat. Med. 2014, 20, 430–435.
6. Tie, J.; Wang, Y.; Tomasetti, C.; Li, L.; Springer, S.; Kinde, I.; Silliman, N.; Tacey, M.; Wong, H.-L.; Christie, M.; et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci. Transl. Med. 2016, 8, 346ra392.
7. Weisenberger, D.J. Characterizing DNA methylation alterations from The Cancer Genome Atlas. J. Clin. Investig. 2014, 124, 17–23.
8. Stirzaker, C.; Zotenko, E.; Song, J.Z.; Qu, W.; Nair, S.S.; Locke, W.J.; Stone, A.; Armstong, N.J.; Robinson, M.D.; Dobrovic, A.; et al. Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value. Nat. Commun. 2015, 6, 5899.
9. Lee, W.H.; Morton, R.A.; Epstein, J.I.; Brooks, J.D.; Campbell, P.A.; Bova, G.S.; Hsieh, W.S.; Isaacs, W.B.; Nelson, W.G. Cytidine methylation of regulatory sequences near the -class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl. Acad. Sci. USA 1994, 91, 11733–11737.
10. Millar, D.S.; Ow, K.K.; Paul, C.L.; Russell, P.J.; Molloy, P.L.; Clark, S.J. Detailed methylation analysis of the glutathione S-transferase (GSTP1) gene in prostate cancer. Oncogene 1999, 18, 1313–1324.
11. Schmidt, B.; Liebenberg, V.; Dietrich, D.; Schlegel, T.; Kneip, C.; Seegebarth, A.; Flemming, N.; Seemann, S.; Distler, J.; Lewin, J.; et al. SHOX2 DNA methylation is a biomarker for the diagnosis of lung cancer based on bronchial aspirates. BMC Cancer 2010, 10, 600.
12. DeVos, T.; Tetzner, R.; Model, F.; Weiss, G.; Schuster, M.; Distler, J.; Gruetzmann, R.; Pilarsky, C.; Habermann, J.K.; Fleshner, P.; et al. Circulating methylated septin 9 DNA in plasma is a biomarker for colorectal cancer. Gastroenterology 2009, 136, A623.
13. Lange, C.P.E.; Campan, M.; Hinoue, T.; Schmitz, R.F.; van der Meulen-de Jong, A.E.; Slingerland, H.; Kok, P.J.M.J.; van Dijk, C.M.;Weisenberger, D.J.; Shen, H.; et al. Genome-scale discovery of DNA-methylation biomarkers for blood-based detection of colorectal cancer. PLoS ONE 2012, 7, e50266.
14. Melotte, V.; Lentjes, M.H.F.M.; van den Bosch, S.M.; Hellebrekers, D.M.E.I.; de hoon, J.P.J.; Wouters, K.A.D.; Daenen, K.L.J.; Partouns-Hendriks, I.E.J.M.; Stessels, F.; Louwagie, J.; et al. N-Myc downstream-regulated gene 4 (NDRG4): A candidate tumor suppressor gene and potential biomarker for colorectal cancer. J. Natl. Cancer Inst. 2009, 101, 916–927.
15. Mitchell, S.M.; Ross, J.P.; Drew, H.R.; Ho, T.; Brown, G.S.; Saunders, N.F.W.; Duesing, K.R.; Buckley, M.J.; Dunne, R.; Beetson, I.; et al. A panel of genes methylated with high frequency in colorectal cancer. BMC Cancer 2014, 14, 54.
16. Wagner, K.J.; Cooper, W.N.; Grundy, R.G.; Caldwell, G.; Jones, C.;Wadey, R.B.; Morton, D.; Schofield, P.N.; Reik, W.; Latif, F.; et al. Frequent RASSF1A tumour suppressor gene promoter methylation inWilms’ tumour and colorectal cancer. Oncogene 2002, 21, 7277–7282.
17. Avraham, A.; Uhlmann, R.; Shperber, A.; Birnbaum, M.; Sandbank, J.; Sella, A.; Sukumar, S.; Evron, E. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int. J. Cancer 2012, 131, E1166–E1172.
18. Brait, M.; Sidransky, D. Cancer epigenetics: Above and beyond. Toxicol. Mech. Methods 2011, 21, 275–288.
19. Mahon, K.L.; Qu, W.; Devaney, J.; Paul, C.; Castillo, L.;Wykes, R.J.; Chatfield, M.D.; Boyer, M.J.; Stockler, M.R.; Marx, G.; et al. Methylated glutathione S-transferase 1 (MGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer. Br. J. Cancer 2014, 111, 1802–1809.
20. Dietrich, D.; Kneip, C.; Raji, O.; Lloglou, T.; Seegebarth, A.; Schlegel, T.; Flemming, N.; Rausch, S.; Distler, J.; Fleischhacker, M.; et al. Performance evaluation of the DNA methylation biomarker SHOX2 for the aid in diagnosis of lung cancer based on the analysis of bronchial aspirates. Int. J. Oncol. 2012, 40, 825–832.
21. Fantony, J.J.; Abern, M.R.; Gopalakrishna, A.; Owusu, R.; Jack Tay, K.; Lance, R.S.; Inman, B.A. Multi-institutional external validation of urinary TWIST1 and NID2 methylation as a diagnostic test for bladder cancer. Urol. Oncol. 2015, 33, 387.e1–387.e6.
22. Chang, Y.S.; Lin, C.Y.; Yang, S.F.; Ho, C.M.; Chang, J.G. Analysing the mutational status of adenomatous polyposis coli (APC) gene in breast cancer. Cancer Cell Int. 2016, 16, 23.
23. Sun, K.; Jiang, P.; Chan, K.C.; Wong, J.; Cheng, Y.K.; Liang, R.H.; Chan, W.K.; Ma, E.S.; Chan, S.L.; Cheng, S.H.; et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc. Natl. Acad. Sci. USA 2015, 112, E5503–E5512.
24. Lehmann-Werman, R.; Neiman, D.; Zemmour, H.; Moss, J.; Magenheim, J.; Vaknin-Dembinsky, A.; Rubertsson, S.; Nellgård, B.; Blennow, K.; Zetterberg, H.; et al. Identification of tissue-specific cell death using methylation patterns of circulating DNA. Proc. Natl. Acad. Sci. USA 2016, 113, E1826–E1834.
25. Snyder, M.W.; Kircher, M.; Hill, A.J.; Daza, R.M.; Shendure, J. Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 2016, 164, 57–68.
26. Lange, C.P.E.; Laird, P.W. Clinical applications of DNA methylation biomarkers in colorectal cancer. Epigenomics 2013, 5, 105–108.
27. Kristensen, L.S.; Raynor, M.P.; Candiloro, I.; Dobrovic, A. Methylation profiling of normal individuals reveals mosaic promoter methylation of cancer-associated genes. Oncotarget 2012, 3, 450–461.
28. Pedersen, S.K.; Baker, R.T.; McEvoy, A.; Murray, D.H.; Thomas, M.; Molloy, P.L.; Mitchell, S.; Lockett, T.; Young, G.P.; LaPointe, L.C. A two-gene blood test for methylated DNA sensitive for colorectal cancer. PLoS ONE 2015, 10, e0125041.
29. Symonds, E.L.; Pedersen, S.K.; Baker, R.T.; Murray, D.H.; Gaur, S.; Cole, S.R.; Gopalsamy, G.; Mangira, D.; LaPointe, L.C.; Young, G.P. A blood test for methylated BCAT1 and IKZF1 vs. a fecal immunochemical test for detection of colorectal neoplasia. Clin. Transl. Gastroenterol. 2016, 7, e137.
30. Pedersen, S.K.; Symonds, E.L.; Baker, R.T.; Murray, D.H.; McEvoy, A.; Van Doorn, S.C.; Mundt, M.W.; Cole, S.R.; Gopalsamy, G.; Mangira, D.; et al. Evaluation of an assay for methylated BCAT1 and IKZF1 in plasma for detection of colorectal neoplasia. BMC Cancer 2015, 15, 654.
31. Edge, S.B.; Byrd, D.R.; Compton, C.C.; Fritz, A.G.; Greene, F.L.; Trotti, A. AJCC Cancer Staging Manual, 7th ed.; Springer: New York, NY, USA, 2010.
32. Kulis, M.; Merkel, A.; Heath, S.; Queirós, A.C.; Schuyler, R.P.; Castellano, G.; Beekman, R.; Raineri, E.; Esteve, A.; Clot, G.; et al. Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nat. Genet. 2015, 47, 746–756.
33. Oakes, C.C.; Seifert, M.; Assenov, Y.; Gu, L.; Przekopowitz, M.; Ruppert, A.; Wang, Q.; Imbusch, C.D.; Serva, A.; Koser, S.D.; et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat. Genet. 2016, 48, 253–264.
34. Schultz, M.D.; He, Y.; Whitaker, J.W.; Hariharan, M.; Mukamel, E.A.; Leung, D.; Rajagopal, N.; Nery, J.N.; Urich, M.A.; Chen, H.; et al. Human body epigenome maps reveal noncanonical DNA methylation variation. Nature 2015, 523, 212–216.
35. Kristensen, L.S.; Hansen, J.W.; Kristensen, S.S.; Tholstrup, D.; Harsløf, L.B.; Pedersen, O.B.; De Nully Brown, P.; Grønbæk, K. Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin. Epigenet. 2016, 8, 95.
36. Oh, T.; Kim, N.; Moon, Y.; Kim, M.S.; Hoehn, B.D.; Park, C.H.; Kim, T.S.; Kim, N.K.; Chung, H.C.; An, S. Genome-wide identification and validation of a novel methylation biomarker, SDC2, for blood-based detection of colorectal cancer. J. Mol. Diagn. 2013, 15, 498–507.
37. Xue, M.; Lai, S.C.; Xu, Z.P.; Wang, L.J. Noninvasive DNA methylation biomarkers in colorectal cancer: A systematic review. J. Dig. Dis. 2015, 16, 699–712.